Actelion Ltd.
is a leading
biopharmaceutical
company focused
on the discovery,
development
and commercialization
of innovative drugs
for diseases
with significant
unmet medical needs.

ACTELION DELIVERS STRONG HALF YEAR OPERATIONAL AND FINANCIAL RESULTS

Jean-Paul Clozel, CEO “In the first half of 2014
we have made great strides in delivering on
our strategy; by growing our PAH franchise,
by advancing our specialty franchises and
by optimizing our profitability.”

Jean-Paul Clozel, CEO “In the first half of 2014
we have made great strides in delivering on
our strategy; by growing our PAH franchise,
by advancing our specialty franchises and
by optimizing our profitability.”

Global Actelion

Hotspot of possibilities

Actelion has subsidaries in over 30 countries, covering all major pharmaceutical markets worldwide

Hotspot of possibilities

Actelion has subsidaries in over 30 countries, covering all major pharmaceutical markets worldwide

Shareprice

ATLN SIX Swiss Exchange

Shareprice
At 17:30:59 CET 30/09/2014
CHF 112,30Up Down image
+1,20 (+1,08%)